1. Sucampo Pharmaceuticals, INC.

2. Overview Background: Sucampo is a pharmaceutical company focused on the development and commercialization of medicines based on prostones. The therapeutical value of prostones was discovered by co-founder Dr. Ryuiji Ueno. In 1996 Dr. Ryuji Ueno paired up with Dr. Sachiko Kuno to form what is currently known as Sucampo. Together they hold Ph.D. ‘s in industrial biochemistry, medicinal chemistry, and pharmacology. Sucampo was taken public on August 2, 2007 with 3, 750,000 class A common shares priced at $11.50 per. What are prostones? Prostones are a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focusing on prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology based inflammatory disorders. Key DataLocations Stock Exchange: NASDAQ Employees: 77Sucampo Pharma Americas Ticker: SCMPFiscal Year End: Dec. 31 st Sucampo Pharma Europe Share Price: $7.10Auditor:PricewaterhouseSucampo AG in Switzerland Market Cap:$306. 88 MSucampo Pharma, Ltd. In Japan

3. Contemporary Outlook The current state of Sucampo is a positive one. Management As of recently Dr. Ryuiji Ueno stepped down as CEO of Sucampo. Replacing him is Peter Greenleaf a seasoned professional in the pharmaceutical industry. Peter previously held top management positions at Medimmune and Cenetor Biotech. This will allow Dr.Ueno to continue developing drugs for Sucampo. Products Amitiza is essential for Sucampos current and future success with nearly 8 million prescriptions over the past 8 years. Since Amitizas inception it has experience d an average month over month prescription increase of 31%. In the United States Amitiza is the only drug approved for opioid-induced constipation. Rescula is generating substantial supporting revenue with Q1 2014 sales of $6.1 million vs. $2.2 million sales in Q1 2013. I would like to see Sucampo increase the name recognition of Rescula.. Ion Channel activator is currently in phase 11a of clinical trials. We cant expect this drug for at least 3-4 years. Every year 1.4 million individuals are diagnosed with spinal stenosis. Cobiprostone has just completed phase 1 of clinical trials. We can expect to see this drug for 5 + years. With 123,000 incidences oral muscotis in the U.S. per year. This market is wide open because there is currently not a cure.

4. Future Outlook Revenue Sucampo will be relying on Amitiza for the future. With Rescula providing nearly 1/4 th the revenue that Amitiza provides and product pipelines in the midst of stage 2 clinical trials. We can’t expect additional supporting revenue for quite some time. On the upside Amitiza is patented until 2020 which means we will not see a generic any time soon. Future of Amitiza The number of prescriptions for Amitiza should drastically increase within the next 10 years. Supporting evidence shows that 50 million U.S. citizens will reach the target age of constipation in the next 10 years. I predict the CIC (chronic idiopathic constipation) therapeutical drug market to reach 5 billion by 2024. Which leaves room for rival drugs like LinaClotide and MiraLax. Competitors Amitiza is experiencing pressure from competitive drugs like LinaClotide and MiraLax. While LinaClotide is running a close second it has not been approved for the 3 rd indication which is Opoid- induced- constipation. Pipelined Revenue Sucampo is a financially sound company with all directions pointing up. If everything goes to plan we can expect to see two new drugs produced by Sucampo. These two products ( Ion Channel Activator and Cobriprostone ) could add an estimated 70-100 million dollars in revenue by 2020.